Sleeping bug: scientists identify drug resistance mechanism

March 2012
Africa Health;Mar2012, Vol. 34 Issue 3, p12
Trade Publication
The article focuses on the study conducted by the researchers in Greta Britain, which reveals several ways by which parasite Trypanosoma brucei can resist drugs used in treating sleeping sickness.


Related Articles

  • Gambiense sleeping sickness: re-emerging and soon untreatable? Van Nieuwenhove, Simon // Bulletin of the World Health Organization;2000, Vol. 78 Issue 11, p1283 

    Editorial. Comments on the return of sleeping sickness caused by Trypanosoma brucei gambiense. Deterioration and disruption of control activities; Problems on the implementation of active case detection and successful treatment; Gap between scientific progress and the implementation of...

  • The Kinetoplastid Chemotherapy Revisited: Current Drugs, Recent Advances and Future Perspectives. Castillo, E.; Dea-Ayuela, M. A.; Rangel, M.; Bolás-Fernández, F.; González-Rosende, M. E. // Current Medicinal Chemistry;Nov2010, Vol. 17 Issue 33, p4027 

    No abstract available.

  • A Molecular Mechanism for Eflornithine Resistance in African Trypanosomes.  // PLoS Pathogens;Nov2010, Vol. 6 Issue 11, p1 

    No abstract available.

  • Diverse Effects on Mitochondrial and Nuclear Functions Elicited by Drugs and Genetic Knockdowns in Bloodstream Stage Trypanosoma brucei. Worthen, Christal; Jensen, Bryan C.; Parsons, Marilyn // PLoS Neglected Tropical Diseases;May2010, Vol. 4 Issue 5, p1 

    Background: The options for treating the fatal disease human African trypanosomiasis are limited to a few drugs that are toxic or facing increasing resistance. New drugs that kill the causative agents, subspecies of Trypanosoma brucei, are therefore urgently needed. Little is known about the...

  • Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Pepin, Jacques; Khonde, Nzambi // Bulletin of the World Health Organization;2000, Vol. 78 Issue 11, p1284 

    Compares the effectiveness of 7 days of intravenous eflornithine with the standard 14-day regimen in the treatment of late-stage Trypanosoma brucei gambiense trypanosomiasis. Use of a randomized controlled trial; Death of some patients during treatment; Difference in response to treatment...

  • Scientists Find 'Revolutionary' Technique to Probe Resistance. Kingman, Sharon // BioWorld International;2/1/2012, Vol. 17 Issue 5, p1 

    The article focuses on a probing method developed by David Horn and colleagues at the London School of Hygiene and Tropical Medicine (LSHTM) that could help gather insights into the mechanisms of drug resistance in unicellular parasite Trypanosoma brucei which causes the human African...

  • New Clues to Sleeping Sickness.  // JAMA: Journal of the American Medical Association;1/2/2013, Vol. 309 Issue 1, p20 

    The article informs that a new research conducted by the scientists of Germany, Sweden and the U.S. has explained the structure of a key enzyme named "Trypanosoma brucei cysteine protease cathepsin B," (TbCatB) from the parasite that causes African trypanosomiasis or sleeping sickness.

  • Estimates of the duration of the early and late stage of gambiense sleeping sickness. Checchi, Francesco; Filipe, João A. N.; Haydon, Daniel T.; Chandramohan, Daniel; Chappuis, François // BMC Infectious Diseases;2008, Vol. 8 Issue 1, Special section p1 

    Background: The durations of untreated stage 1 (early stage, haemo-lymphatic) and stage 2 (late stage, meningo-encephalitic) human African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense are poorly quantified, but key to predicting the impact of screening on transmission....

  • Estimating the burden of rhodesiense sleeping sickness during an outbreak in Serere, eastern Uganda. Fèvre, Eric M.; Odiit, Martin; Coleman, Paul G.; Woolhouse, Mark E. J.; Welburn, Susan C. // BMC Public Health;2008, Vol. 8 Issue 1, p96 

    Background: Zoonotic sleeping sickness, or HAT (Human African Trypanosomiasis), caused by infection with Trypanosoma brucei rhodesiense, is an under-reported and neglected tropical disease. Previous assessments of the disease burden expressed as Disability-Adjusted Life Years (DALYs) for this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics